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Objective: To examine the amount of cell-free and cell-associated virus in  cervicovaginal secretions (CVS) of HIV- 
infected women. 
Methods: Paired cervicovaginal and blood samples from 61 seropositive women were quantitatively evaluated by 
competitive polymerase chain reaction (cPCR) and reverse transcription-PCR (cRT-PCR) for: (1) genomic RNA from 
plasma and cell-free CVS, and (2) unspliced (u/s) RNA transcripts and proviral DNA in cells from secretions. 
Results: HIV DNA was detected in 42.6%, u/s transcripts in 32.7% and cell-free HIV RNA in 31.1% of 61 cervicovaginal 
samples. The median copy numbers of HIV DNA, u/s transcripts, and cell-free RNA were 125 copies/105 cells, 
40 copies/105 cells, and 300 copies/mL of secretion, respectively. Nineteen of 26 (73.1%) and 17 of 26 (65.3%) women 
positive for DNA were also positive for RNA transcripts and cell-free RNA, respectively (P<O.OOI). A significant 
correlation between the amounts of cell-free and u/s transcripts was also found (Spearman Rho 0.618, P=0.014). The 
prevalences of u/s transcripts and cell-free RNA were 42.6% and 53.8% respectively among patients with detectable 
blood RNA, and 22.9% (P=O.O9) and 14.3% (P=0.0017) among patients with undetectable blood RNA. In stepwise logistic 
regression, cell-free RNA was independently associated with the presence of detectable blood viremia. The amount of 
HIV DNA was lower among subjects currently under treatment (50 copies/105 cells) than in  untreated subjects (250 
copies/105 cells) (P=0.037). 
Conclusions: Both cell-free and cell-associated HIV could be detected and quantitated in CVS, providing a means to  
examine the level of viral activity in  the female genital tract. 
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INTRODUCTION 
Heterosexual transmission is the chief mode of 
acquisition of HIV and is responsible for the majority 
of infections worldwide [l]. Mother-to-child trans- 
mission occurs in utero, intrapartum, and postnatally, 
with transmission rates ranging from 14% to 39% 
[2,3]. 
HIV particles in genital secretions are directly 
responsible for infection of the new host, and indirect 
evidence suggests that infected cervicovaginal secre- 
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tions (CVS) are also implicated in vertical transmission 
at birth [3,3]. 
Although the biological factors associated with the 
presence and concentration of HIV-1 in semen have 
been extensively studied [+lo], precise data on HIV-1 
quantitation in CVS are limited [I 1-19]. Concerning 
the presence of virus-infected cells in cervicovaginal 
samples, our knowledge is limited to qualitative analysis 
of proviral DNA [13,15], and only indirect evidence 
suggests that HIV-1 is actively produced in the female 
genital tract [20]. A considerable problem with these 
studies concerns the lack of uniformity in the sampling 
techniques used. In fact, although cervicovaginal lavage 
reflects the composition of the CVS more accurately, 
the amount of secretion contained in each sample and 
the precise amount of virus are difficult to estimate. 
The amount of virus can be more easily calculated from 
a swab, but swabbing may provoke bleeding into the 
genital tract. 
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Several studies have shown that a competitive PCR 
(cPCR) is the method of choice for quantitative ana- 
lysis of viral nucleic acids present in very small amounts 
in clinical samples [21]. In the last few years, the 
quantitative analysis of HIV-1 viremia, viral gag tran- 
scripts in peripheral blood mononuclear cells (PBMCs), 
and proviral DNA sequences obtained by cPCR and 
competitive reverse transcription-PCR (cRT-PCR), 
have been used extensively to examine the level of 
HIV-1 activity in infected patients, provihng a more 
complete evaluation of the molecular profile of HIV-1 
infection [22-251. 
The purpose of this study was to provide a precise 
quantitative assessment of HIV-1 cell-free and cell- 
associated nucleic acids in CVS. We applied a sensitive 
cPCR and cRT-PCR [22] for simultaneous quanti- 
tation of HIV-1 proviral DNA and RNA-specific 
transcripts in cervicovaginal cells, in addition to HIV 
extracellular RNA in CVS. 
MATERIALS AND METHODS 
Study population 
From March to October 1997, cervicovaginal samples 
were obtained from 61 seropositive women attending 
the colposcopic clinic of the Department of Obstetrics 
and Gynecology of the University of Pavia for periodic 
screening for lower genital tract neoplasia. Inclusion 
criteria were: (1) informed consent; (2)  absence of 
symptoms suggesting genitourinary infections (leuko- 
rrhoea, pruritus); (3) non-pregnant status; (4) absence 
of visible blood in secretions; (5) abstinence from 
unprotected sexual intercourse for at least 3 days prior 
to sampling. 
Clinical staging was defined using the Centers for 
Disease Control (CDC) classification system [26]. 
Patients were also classified according to their anti- 
retroviral treatment status at the time of sampling: no 
treatment, previous antiretroviral treatment and active 
current treatment. No modification of treatment status 
was found in the 2 months prior to sampling. Patients 
in the active treatment group received either two 
nucleoside analogs (zidovudine plus lamivudine) or two 
nucleoside analogs plus protease inhibitors (zidovudine 
plus lamivudine plus indinavir). Peripheral blood 
samples were collected at the same time as the cervico- 
vaginal samples for estimating CD4+ lymphocyte cell 
counts and quantitating HIV RNA in plasma. 
Clinical samples and nucleic acid purification 
After a careful speculum examination, CVS were 
obtained both by gently rotating a (Dacron) swab 
within the posterior fornix, and by lavage after 
insertion of 10 mL of RPMI 1640 medium into the 
vagina, followed by aspiration of the suspension after 
allowing 1 min for pooling. All samples were kept at 
4OC and delivered to the laboratory within 2 h of 
collection. Cell-free CVS were obtained from swab 
samples. The swabs were incubated in 1 mL of RPMI 
1640 medium for 10 min at 37OC, vortexed and 
centrifuged at 10008 for 10 min. The supernatant was 
removed, and 100-pL aliquots were frozen at -8OOC 
until used for extraction of cell-free HIV-1 RNA. CVS 
cell pellets were obtained from lavage samples. The cells 
were washed twice with physiologic s a h e  solution 
containing <0.4% NP40 and 0.05% sodium azide as 
previously described [16]. The cells then were counted 
and immediately processed for DNA and RNA 
extraction. CVS were not collected during men- 
struation. Swab samples were examined under the 
microscope upon arrival to the laboratory and again 
after centrifugation, to confirm the absence of red 
blood cells and spermatozoa. The possible presence of 
blood contamination was fbrther checked by using a 
routine screening test for hemoglobin detection (reactive 
strips, Bayer AG, Leverkusen, Germany; multistic-10 
visual). The lower limit of hemoglobin detection by 
this method is equivalent to 25 000 red blood cells/mL 
of sample. EDTA-treated peripheral blood was 
centrifuged at 6008 for 10 min, the plasma was 
recovered, and platelets and cell debris were removed 
by centrifuging at l800g for 10 min. Clarified plasma 
was then stored in 200-pL aliquots at -8OOC. RNA 
was extracted from cervicovaginal and plasma samples 
using the guanidmium thiocyanate method as pre- 
viously described [27]. 
RNA samples (10 pL, equivalent to lo5 cells) 
obtained from cervicovaginal cells were treated 
with 2.5 U of DNase I (RNase-free, Boehringer 
Mannheim, Penzberg, Germany). After incubation at 
37OC for 10 min and at 93OC for 10 min to inactivate 
DNase I, samples were cooled on ice. RNA samples 
were aliquoted and stored at -80°C until used. DNA 
was extracted from the nuclei of cervicovaginal cells to 
minimize contamination with unintegrated DNA [28]. 
Pelletted nuclei were resuspended at a concentration of 
107/mL in lysis buffer (10 mmol/L Tris-HC1, pH 8.3, 
50 mmol/L KC1, 0.5% Tween-20, 0.5% NP40, 
1.5 mmol/L MgC12) and treated with proteinase K 
(120 mg/L) at 56OC for 4 h. The proteinase was then 
inactivated by heating at 95OC for 10 min. 
The following substrates were analyzed using 
quantitative cPCR and cRT-PCR: (1) genomic RNA 
from plasma and from cell-free CVS; (2) virus-specific 
unspliced (u/s) RNA transcripts from cervicovaginal 
cells; and (3) proviral HIV-1 DNA from nuclei of 
cervicovaginal cells. 
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Detection and quantitation of HIV-1 RNA and DNA 
Qualitative analysis of specific RNA and DNA 
sequences was first performed by PCR using the SK 
462/431 pair of primers [29]. RNA samples (10 pL, 
equivalent to 100 pL of plasma, 100 pL of cell-free 
CVS, or 10' cervicovaginal cells) were reverse- 
transcribed for 30 min at 42°C in a 20-pL final volume 
containing 1 X PCR reaction buffer (50 mM NaC1, 
10 mM Tris-HC1 (pH 8.3), 1.5 mh4 MgC12), 100 U of 
Moloney murine leukemia virus reverse transcriptase 
(RT, Gibco Life Technologies, Paisley, UK), 20 pmol 
of the SK 431 primer, 0.2 n M  (each) deoxynucleoside 
triphosphate (dNTP) and 20 U of Rnasin (Gibco Life 
Technologies). The cDNA was then heated in the same 
mixture for 5 min at 95°C. Each cDNA (10 pL) and 
DNA sample (10 pL, equivalent to lo5 cells) was 
amplified in a 50-pL mixture containing, at a final 
concentration, 1 X PCR reaction buffer, 0.2 mM 
(each) dNTF', 50pmol of (each) primer (SK 462 and 
SK 431) and 1.5 U of Taq DNA polymerase (Perkin- 
Elmer Cetus, Enieryville, California, USA). The PCR 
profile (20 s of denaturation at 94"C, 20 s of annealing 
at 6OoC, 30 s of extension at 72°C) was repeated for 50 
cycles. At the end of the last cycle, the DNA was 
further extended at 72OC for 10 min. 
To ensure that sufficient DNA was present in the 
preparation fiom cervicovaginal cells, and that inhibi- 
tors were absent from the reaction mixtures, the 
P-globin gene was amplified in the same DNA samples 
[30]. Although RNA from CVS is purified by 
phenol-chloroform extraction and treated with DNase 
I, the substrate specificity of RT-PCR was evaluated by 
testing RNA samples also for amplification without the 
reverse transcription step. Quantitation of HIV-1 DNA 
and RNA was performed using a competitive PCR and 
RT-PCR as previously described in detail [22]. This 
method consists of the reverse transcription and/or 
amplification of two similar RNA or DNA templates, 
the wild-type template to be quantified and a known 
amount of the internally deleted synthetic template, 
both with identical recognition sites for SK38/SK39 
primers. The primer set is specific for a highly con- 
served gag fragment of the HIV-1 genome, and the 
method has proved to be useful in the quantitative 
analysis of HIV-1 genomic RNA from plasma, u/s 
RNA transcripts, and proviral DNA from PBMCs 
[22-251. For cervicovaginal samples, quantitative results 
are expressed as HIV-1 RNA transcripts and HIV-1 
DNA copy number per lo5 cells, and as HIV-1 RNA 
cell-free copy number per mL of CVS. The dilution 
factor of the CVS with the known amount of transport 
medium (1 mL/swab sample) was taken into account 
for the final calculation of the cell-free HIV-1 RNA 
copy numbers. Each swab sample contained from 200 
to 300 pL of CVS. In our experimental conditions, the 
lower limit of detection of the assay is two DNA or 
RNA copies/lO' cells, 20 RNA copies/mL of CVS, 
and 200 RNA copies/mL of plasma. 
Statistical analysis 
The Mann-Whitney test and Fisher's exact test were 
used to compare continuous and categorical variables, 
respectively. Because of the asymmetric distribution of 
data, a non-parametric approach (Spearman rank 
correlation coefficient) was employed to analyze the 
association between levels of HIV-1 nucleic acids. 
Logistic regression analysis was used to predict the 
presence/absence of HIV-related nucleic acid in 
cervicovaginal samples. Given the small number of 
cases, we used a stepwise approach with backward 
elimination of non-significant terms to obtain more 
rigorous models. The P values for inclusion or removal 
of terms from logistic models were set at 0.1 and 0.05, 
respectively. 
Sixty-one seropositive women were enrolled in this 
study, and paired cervicovaginal and blood samples 
were obtained simultaneously from all subjects. Control 
samples were obtained from two HIV-1-seronegative 
healthy subjects. The mean age was 30.5 f 3.8 (SD) 
years, and the mean time since the first positive blood 
test was 7 years (range 0-13). According to the CDC 
classification system, 35 (57.4%) patients were at stage 
A, while 10 (16.4%) and 16 (26.2%) were at stage B 
and C, respectively. The median CD4 cell count was 
264 (range 0-990). CD4+ cell counts were <200 mm3 
in 36 patients (59%), between 200 and 499 in 13 
(21.3%), and 2500 in 12 (19.7%). Forty-five patients 
(73%) were currently taking antiretroviral drugs. 
Thirty-one (68.8%) of these subjects were currently 
receiving two nucleoside analogs, and 14 (31.1%) two 
nucleoside analogs plus protease inhibitors. Of the 
remaining 16 subjects, four were treatment naive and 
12 had stopped antiretroviral treatment more than 2 
months prior to sampling. Given the small number of 
cases, the patients who were treatment naive and those 
patients who had discontinued treatment were com- 
bined together. The overall prevalence of squamous 
intraepithelial neoplasia on Pap smears was 57.4% 
(35/61). 
Prevalence and quantitative analysis of HIV-1 in 
cervicovaginal samples 
The presence of HIV-1 nucleic acids was first assessed 
by qualitative PCR and RT-PCR analysis. Under our 
experimental conditions, all positive samples had both 
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Table 1 Quantitative molecular data from 26 HIV-1-infected patients who tested positive for HIV-1 DNA in cells of 
cervicovaginal secretions 
Proviral DNA u/s R N A  transcripts HIV R N A  copies/mL HIV RNA copies/mL 
Patient no. copies/1O5 cells copies/I05 cells of cvs of plasma 
1 100 20 3 800 19000 
2 530 50 1000 14000 
3 100 25 300 850 
4 200 25 1000 < 200 
- - < 200 5 200 
6 170 1000 3 500 <200 
7 480 100 1200 <200 
- - 7000 8 150 
9 70 - < 200 
10 250 2000 1500 60000 
11 60 150 200 9000 
12 20 25 300 2400 
13 1500 - - 25 000 
14 200 - - <200 
15 1000 1500 2 500 3 400 
16 10 25 - 2 200 
17 25 5 - 1500 
18 45 24 120 1500 
19 15 15 45 1800 
20 10 - 2 000 
21 200 8 35 1400 
22 25 10 150 1500 
23 150 20 40 2500 
24 50 10 250 10000 
25 350 100 1200 2 500 
26 25 50 500 <200 
- 
- 
Quantitative molecular data were obtained by cPCR and cRT-PCR. Proviral DNA and u/s R N A  transcripts were expressed as copy 
number per lo5 cells obtained from CVS, and HIV-1 R N A  as copy number per mL of CVS (or per mL of plasma). 
-, negative by qualitative RT-PCR; u/s, unspliced CVS, cervicovaginal secretions. 
DNA and RNA levels detectable by quantitative cPCR 
and cRT-PCR. No contamination by proviral DNA 
was detected in RNA samples tested for PCR without 
reverse transcription. Upon checking under the micro- 
scope, none of the samples were excluded by the 
presence of red blood cells or spermatozoa. No hemo- 
globin was detected in swab samples. In cervicovaginal 
cells, HIV DNA was detected in 26 (42.6%) and HIV 
RNA specific transcripts in 20 (32.7%) of the 61 
samples. The median numbers of HIV-1 DNA copies 
and HIV RNA specific transcripts per lo5 cells were 125 
(range 10-1 500) and 40 (range 5-2000), respectively. 
Cell-free HIV RNA was detected in 19 (31.1%) of the 
61 samples obtained by cervicovaginal swabs. The 
median numbers of cell-free HIV-1 genomes was 
300 copies/mL (range 20-3 800). The quantitative 
molecular data from women who tested positive for 
HIV DNA in CVS are given in Table 1. 
Correlation between HIV-1 DNA and HIV-1 RNA in 
cervicovaginal samples 
Among women positive for HIV-1 DNA in CVS, 
RNA transcripts and cell-free RNA were detected in 
73.07% (19/26) and 65.3% (17/26), respectively (chi- 
square test, P<O.OOl). The corresponding figures 
among women who tested negative for HIV-1 DNA 
were 2.8% (1/35) and 5.7% (2/35), respectively. Cell- 
free HIV RNA was detected in 75% (1 5/20) of samples 
positive for RNA-specific transcripts and in 9.8% 
(4141) of the negative samples (P<O.OOl). The amount 
of cell-free RNA was significantly correlated with u/s 
RNA transcript concentration but not with proviral 
DNA concentration (Spearman rank correlation 
coefficients=0.618 and 0.195, P=0.014 and 0.45, 
respectively). 
Association between HIV detection in cervicovaginal 
samples and clinical variables 
Relationships between the presence and concentration 
of HIV in cervicovaginal samples and clinical variables 
such as HIV viremia, stage of HIV disease, CD4+ 
lymphocyte counts, antiretroviral treatment and time 
since first positive HIV blood testing are reported in 
Table 2. The median number of HIV RNA genomes 
in plasma samples was 2950 copies/mL (range 200- 
60 000). 
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Table 2 Relationships between the presence and/or concentration of HIV nucleic acids in cervicovaginal secretions and 
clinical variables 
HIV DNA HIV RNA (u/sa transcripts) 
Median (range) Median (range) Median (range) 
HIV RNA (cell-free) Total No. positive (copies/105 cells) No. positive (copies/105 cells) No. positive (copies/mL) 
HIV blood viremia 
Yes 26 17 100 (10-1500) 12 22 (5-2000) 14 1000 (20-2400) 
No 35 9 200 (10-300) 8 so (20-1000) 5 275 (35-3800) 
Time since seroconversion 
<2 years 8 5 25 (10-200) 4 12.5 (830)  4 98 (35-2400) 
2-5 years 17 6 50 (15-200) 4 87 (20-1000) 5 200 (20-3800) 
>5 years 36 15 200 (10-1500) 12 50 (5-2000) 10 750 (40-2500) 
HIV stage 
A 35 14 125 (10-1500) 10 30 (5-1500) 7 1800 (35-3800) 
B 10 5 200 (25-500) 3 50 (50-100) 3 1000 (500-1200) 
C 16 7 50 (25-250) 7 50 (10-2000) 9 250 (20-1500) 
2 2 0 0 / ~ ~ ~ 3  25 11 150 (10-1500) 9 100 (10-2000) 8 650 (m-mn) 
CD4’ cell count 
< 2 0 0 / ~ ~ 3  36 15 100 (10-1000) 11 20 (5-100) 11 300 (20-3800) 
HIV treatment 
N o  16 9 250 (10-1500) 6 550 (8-200) 5 1500 (35-2500) 
Yes 45 17 50 (10-350) 14 40 (5-150) 14 275 (20-3800) 
W s .  unspliced 
HIV DNA was detectable in cervicovaginal 
samples in 65.3% (17/26) of viremic patients and in 
25.7% (9135) of those with undetectable blood HIV 
R N A  (P=0.003) (Table 2). Despite this correlation, 
nine of 36 women (35%) who tested positive for 
proviral HIV DNA in cervicovaginal cells had 
undetectable levels (<200 copies/mL,) of blood HIV 
RNA.  The prevalences of cervicovaginal R N A  
transcripts and cell-free R N A  among viremic patients 
were 42.6% and 53.8%, respectively. The corres- 
ponding figures among non-viremic patients were 
22.9% (P=0.09 Fisher’s exact test) and 14.3% 
(P= 0.0017) respectively. 
The detection of proviral HIV DNA and cell- 
associated HIV R N A  was not influenced by stage of 
HIV disease, treatment status, CD4’ lymphocyte 
counts or time since HIV seroconversion. The preva- 
lence of cell-free HIV R N A  detection was positively 
correlated with increasing severity of HIV disease (chi- 
square for trend=6.48, P=O.Oll). 
Logistic regression analysis was used to identify the 
factors independently associated with the presence of 
cell-associated and cell-free HIV R N A  in CVS. Given 
the small number of cases, to obtain a reliable estimate 
of the odds ratios we used a stepwise approach with 
backward elimination of non-significant variables. 
Initial models included all the variables of Table 2. The 
results of this modeling are given in Table 3. Detection 
of cell-associated HIV R N A  in cervicovaginal cells was 
independently associated with the presence of proviral 
HIV DNA and cell-free HIV R N A  in CVS. O n  the 
other hand, detection of cell-free HIV R N A  was 
associated with HIV blood viremia in addition to cell- 
associated HIV RNA.  
Table 3 Variables predicting the presence of HIV RNA 
u/s transcripts and cell-free HIV RNA in cervicovaginal 
secretions 
OR (95% CI)” P value 
Variables associated with the presence of HIV RNA u/s 
transcriptsb 
HIV DNA 40.4 (4.2-387) 0.0001 
HIV RNA (cell-free) 7.2 (1.22-41.9) 0.029 
Variables associated with the presence of cell-free HIV RNA’ 
HIV RNA (u/s transcripts) 32.8 (5.9-181.5) <0.0001 
HIV RNA (blood) 8.8 (1.6-49.3) 0.013 
“Odds ratios and 95% confidence intervals. 
bAs obtained by a stepwise logistic regression model with backward 
elimination of non-significant terms, including the presence of 
HIV DNA and cell-free HIV RNA in cervicovaginal secretions 
(yes, no), stage of HIV disease (A, B, C), time since seroconversion 
(<2 years, 2-5 years, > 5  years), CD4+ cell counts (5200,  >300), 
HIV blood viremia (yes, no), and current antirrtroviral treatment 
(yes, no) in the initial model. 
‘As obtained by a stepwise logistic regression model with backward 
elimination of non-significant terms, including the presence of 
HIV DNA and HIV RNA u/s transcripts in cervicovaginal 
secretions (yes, no), stage of HIV disease (A, B, C), time since 
seroconversion (<2  years, 2-5 years, > 5  years), CD4’ cell counts 
(5200, >200), HIV blood viremia (yes, no), and current 
antiretroviral treatment (yes, no) in the initial model. 
u/s, unspliced. 
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Association between HIV amount in cervicovaginal 
secretions and clinical variables 
Although the time since first positive HIV testing did 
not influence the rate of HIV DNA detection in CVS, 
HIV DNA copy number was positively correlated with 
increasing time since HIV seroconversion (Spearman 
rank correlation coefficient = 0.456, P= 0.01 9) (Table 
2). The amounts ofHIV DNA and cell-free RNA were 
also higher among patients not currently taking anti- 
retroviral drugs compared to currently treated subjects 
(P=0.037 and P=0.09, respectively, by Mann- 
Whitney test). 
DISCUSSION 
To evaluate the presence and quantity of HIV in CVS, 
we used both cervicovaginal lavage and endocervical 
swabs. Lavage sampling, which may reflect the com- 
position of CVS better than swabs, was used to quantify 
DNA and RNA transcripts in cells. On the other hand, 
endocervical swabs, in whch the amount of secretion 
present in the sample is known, were used to obtain 
reliable quantitative data on cell-free RNA. Since 
swabbing may provoke bleeding that could introduce 
HIV into the genital tract, samples were taken gently, 
and checked for the presence of blood by microscopic 
and chemical methods. 
The results obtained on the prevalence of HIV 
DNA and RNA are in agreement with, and extend, 
previous stuhes [13,15,16,18,19]. A strong correlation 
was observed between the presence of HIV DNA and 
RNA transcripts in cells, and between HIV DNA and 
cell-free RNA in CVS. 
The absence of blood, as sought by microscopic 
and chemical methods, and our finding of HIV RNA 
in CVS but below the cut-off limit in the plasma of 
some women, demonstrate that specific viral sequences 
detected in CVS do not result fiom contamination by 
blood. In addition, no spermatozoa were detected in 
CVS, and the subjects were selected on the basis of 
abstinence from unprotected sexual intercourse for 3 
days prior to sampling. Moreover, a cross-sectional 
study which included 1201 female sex workers demon- 
strated that HIV-1 shedding in CVS was not associated 
with the presence of spermatozoa [15]. Although the 
cervical epithelium could be the site of HIV infection 
[31], whether the virus was present in epithelial cells or 
in lymphocytes could not be determined in this study. 
Using cRT-PCR, the median copy number of cell-free 
RNA in CVS was 300 copies/ml. This result differs 
quantitatively from the results of a recent report indi- 
cating that cell-free RNA, quantified using RT-PCR 
and an external reference standard curve, averages 
104/mL [15]. This difference could be due to technical 
reasons, with different assays having different levels of 
detection; moreover, it is hffcult to control the tran- 
scription and amplification reaction variables without 
using an internal standard [21]. The median numbers 
of HIV proviral DNA sequences and u/s transcripts 
in cells from CVS were 125 copies/105 cells and 40 
copies/105 cells, respectively. A significant correlation 
was detected between quantitative measurements of 
cell-free RNA and RNA transcripts but not with 
proviral DNA in CVS. Recently, the use of cPCR and 
cRT-PCR to investigate HIV-1 viremia, viral u/s 
transcripts in PBMCs, and proviral DNA, has supplied 
evidence that HIV-1 structural gene transcription and 
complete viral replication can be detected in the blood 
of infected patients [23-251. However, because of the 
complexlty of CVS composition, more specific analytic 
techniques (e.g. detection of different classes of viral 
transcripts), and evaluation of sequential samples &om 
infected women, are required to provide evidence of 
viral replication in the lower female genital tract as a 
source of cell-free virus. 
Although the present study was not begun to 
examine this issue, our results show that antiretroviral 
treatment, either with two nucleoside analogs or with 
two nucleoside analogs plus a protease inhibitor, has no 
effect on the detection rate of HIV in CVS, but reduces 
local viral load significantly. However, because the 
sample size was limited, these preliminary data should 
be confirmed in further and more extensive studies. 
Again, since the number of women with virus detected 
in CVS was low, the influence of other clinical variables 
on the presence and/or amount of HIV in CVS also 
needs further study. However, our results demonstrate 
that the presence of detectable levels of HIV DNA and 
HIV RNA in CVS is not necessarily related to the 
presence of detectable HIV RNA in plasma. Such data 
suggest compartmentalization of the virus in different 
tissue sites, as described in a recent report demon- 
strating HIV in semen of patients on effective highly 
active antiretroviral therapy [32]. 
In addition, no association was found between the 
amount of HIV in CVS and the presence of detectable 
HIV RNA in plasma. These results agree with those of 
other studies [16], and suggest that some factors 
produced locally in the cervicovaginal area (such as 
hormonal influences, mucosal immunity or cytokines) 
may be responsible for the different amounts of virus 
detected. Although the presence and amount of virus 
do not supply any information on the infectivity of 
CVS, our results demonstrate that both cell-fiee and 
cell-associated virus could be quantitated in CVS, thus 
providing a means to study viral activity, the effect of 
antiretroviral treatments, and the biological factors 
associated with the presence and concentration of HIV 
in the female genital tract. 
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